The US FDA has approved cefiderocol (Fetroja), a siderophore cephalosporin that inhibits bacterial cell wall synthesis. Fetroja is the first approved antibiotic that functions as a siderophore.
Only one-third of patients entering the emergency department with a suspected UTIs actually have evidence of infection, however, almost all were treated with antibiotics, according to research presented at ECCMID.
A Phase II trial has demonstrated that a new investigational antibiotic, cefiderocol, is as effective as the current standard-of-care for treating complicated UTIs caused by multi-drug resistant bacteria.
